TSLP and atopic eczema: This immunomodulatory effect suppresses production of key Th2-associated pro-inflammatory cytokines—including IL-4, IL-13, IL-31, IL-33, CCL17, and thymic stromal lymphopoietin (TSLP)—culminating in marked attenuation of clinical features (erythema, edema), reduced systemic chemokine levels, and diminished dermal infiltration of inflammatory lymphocytes, particularly CD4 + T cells and eosinophils, in a 2,4-dinitrochlorobenzene (DNCB)-induced murine model of atopic dermatitis (Lu et al. 2023; Liu et al. 2007; Varricchi et al. 2018).